Key takeaways
- Your dose may rise early and then hold for a long stretch. Holding is not failing.
- Progress is fastest in the first months and slows in the middle, which is where most people stop.
- Reaching your goal weight is a decision point, not an automatic ending.
- There are three real options at that point, and most people are only ever told about one.
Most people start a GLP-1 with no idea what the next twelve months hold. Here is the honest shape of it. Your dose may rise early, then hold. Progress is fastest in the first months and slows after that, which is exactly when most people quit. And the moment you reach your goal is a decision point, not an ending. There is no schedule that fits everyone, and your physician sets yours based on how you respond.
Starting
Appetite changes first, often within days. Side effects, when they happen, are most common early and most often settle. This stretch is about tolerance rather than results. Your physician chooses where you begin.
Finding the dose that fits you
Your dose may increase after the first month. It may increase again. It may hold where it is for a long time, and holding is not failing. Some people do best well below the maximum.
You will not find a titration schedule on this page, and that is deliberate. What is right depends on how you respond and how you tolerate it, which makes it a clinical decision your physician makes with you rather than something a website can tell you.
The middle, where most people stop
The scale slows. That is normal, it is not the medication failing, and it is the point at which most people give up.
Two things matter more here than anywhere else: protein and resistance training. Around a quarter of what you lose is lean tissue if you do nothing about it. This is the part worth reading before you get there.
Approaching your goal
The number tends to arrive before the habits do. Reaching your goal weight is where you decide what happens next, and it is much easier to decide that in advance than in the week you get there.
Where you are, and what matters there
The pace of change is not steady. Move the slider to see what is usually happening, and what is worth your attention at that point.
Finding your dose
Appetite is well down. Your dose may rise again or hold.
How quickly things change. Fastest early, then steadily flatter.
A general picture for education, not a prediction, and not a dosing schedule. Everyone responds differently and your physician decides what happens and when.
What happens after: three honest paths
1. Stop
Works when the habits underneath are genuinely built. Appetite returns either way. Without a plan, this is the point at which weight most commonly comes back.
The Bridge, our post-GLP-1 maintenance protocol →2. Stay on a maintenance dose
Some people remain on a lower ongoing dose long term under physician supervision, rather than stopping outright.
3. Move to a microdose
A sub-clinical dose, meaning lower than the amount used for weight loss, taken for reasons other than losing weight.
How microdosing works →Most people are only ever told about the first one. All three are real options, and which one suits you is a conversation with your physician rather than a default.
Why anyone would stay on it after the weight is gone
GLP-1 receptor agonists are being studied well beyond weight. These are areas of active research, each with its own literature:
- Cardiovascular outcomesRates of heart attack, stroke and cardiovascular death, in people with and without diabetes.Read the article
- Kidney functionProgression of chronic kidney disease and kidney-related death.Read the article
- Liver fatFat and inflammation in metabolic dysfunction-associated steatotic liver disease.Read the article
- Sleep apneaSeverity of obstructive sleep apnea and reliance on overnight breathing support.Read the article
- Blood pressureAmbulatory blood pressure, studied as one route to the cardiovascular findings.See the research
- InflammationInflammatory markers, one proposed mechanism for effects that exceed weight change.Read the article
- Insulin sensitivityHow the body handles glucose, separately from how much weight was lost.Read the article
- Visceral fatFat stored around the organs rather than under the skin.Read the article
- Knee osteoarthritisJoint pain and function in knee osteoarthritis, an active area of trial work.Read the article
- Bone densityWhether bone is preserved or lost alongside fat during weight reduction.Read the article
- PCOSMetabolic and hormonal features of polycystic ovary syndrome.Read the article
- FertilityFertility and conception, including what changes when weight changes.Read the article
- Alcohol useReported reductions in alcohol intake and craving. Early and mixed.Read the article
- Nicotine and substance usePreliminary work on nicotine and other substance use disorders. Findings remain variable.See the research
- Reward and dopamine pathwaysHow these drugs act on the brain's reward circuitry, which is the proposed mechanism behind the appetite and craving effects.Read the article
- NeurodegenerationOngoing research in Alzheimer's and Parkinson's disease. Early stage.Read the article
The reviews these areas come from
- The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine (The Lancet), 2025. Link
- The expanding scope of GLP-1 receptor agonists: six uses beyond diabetes. Review, 2025. Link
- GLP-1 receptor agonists beyond diabetes management. Review. Link
- Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: a target trial emulation study. Study. Link
- GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. Review. Link
That is research, not a promise, and none of it is a reason on its own to take a medication. It is why stopping the moment the weight is gone is not automatically the right answer, and why it is worth asking your physician what you are actually optimising for.
Common questions
How long do people stay on a GLP-1?
There is no fixed course. Some people use one for a defined period and stop, some remain on a lower ongoing dose, and some move to a sub-clinical dose for reasons other than weight. How long you stay on it is a decision you make with your physician, based on why you started and what has changed.
Will my dose keep going up?
Not necessarily. A dose may increase early, then hold for a long stretch, and holding is not failing. Some people do best well below the maximum. Your physician decides based on how you respond and how you tolerate it, which is why no schedule printed on a website can tell you what yours will be.
Is it normal for weight loss to slow down after a few months?
Yes. Progress is fastest early and slows after that. The middle stretch is where the scale moves least and where most people stop, which is also when protein intake and resistance training matter most.
What happens if I just stop?
Appetite generally returns. Whether the weight does depends largely on whether the habits underneath it were built while you were losing. Stopping without a plan is the point at which weight most commonly comes back.
What does microdosing a GLP-1 mean?
A sub-clinical dose, meaning lower than the amount used for weight loss, taken for reasons other than losing weight. It is a physician-prescribed option, not a way to self-manage a lower dose.
Can I stay on a GLP-1 after I reach my goal weight?
That is a conversation with your physician, and it is a real option rather than an unusual one. Reaching a goal weight is a decision point, not an automatic stopping point.
Do I have to be on it forever?
No. Some people stop, some stay on a maintenance dose, and some move to a sub-clinical dose. The point is that all three are choices, and it is worth deciding which one you are aiming at before you arrive.
Why would anyone take a GLP-1 for something other than weight?
GLP-1 receptor agonists are under active study across a wide range of areas beyond weight, including cardiovascular and kidney outcomes, sleep apnea, inflammation and liver fat. That research is ongoing and is not a promise of benefit, but it is why stopping the moment the weight is gone is not automatically the right answer.
